anonymous
Guest
anonymous
Guest
Can't wait to see how KC screws everyone over on bonuses/raises this year. Perhaps he can push the stock down to 25 by the end of Q2.
Natera is coming for usYup. Sell everything in Exact before it really tanks. It’s going to be rough
If an email comes out saying a blood test under development needs to meet a minimum 74% sensitivity to launch(74% being the FIT test sensitivity), you can be assured that blood test isn't currently meeting that minimum. Guardant Shield is at 83% sensitivity.Natera is coming for us
Nobody is coming for you. This company never makes a profit. If anyone was going to buy you Pfizer would have when you collaborated on Cologuard. Exact Science will just close and go bankrupt.Natera is coming for us
ThisNobody is coming for you. This company never makes a profit. If anyone was going to buy you Pfizer would have when you collaborated on Cologuard. Exact Science will just close and go bankrupt.
More likely to be bought out by one of the large diagnostic companies. Cologuard will face significant competition in the future but will still play a role. Other companies will have a more diversified portfolio to absorb the slowing or negative growth. The hope was liquid biopsy would be the next growth engine but reading what’s out there we will not be best in class. We should be ok employment wise for a while. Stock price who the heck knows. At some point you have to show a profit unless the growth was off the charts which does not seem to be the case. Fourteen years is a long time and growth is slowing.This
Why buy a test that hasn't been improved in 14 years?. The size of sample collected is obscene. Others can do the same test with 1/50th the sample volume. Drop a small sample in mail or at clinic instead of paying ups god knows how much to ship a massive bucket for each patient. Great job Kevin. 100 mil a quarter dropped on R&D and nothing to show since 2012.More likely to be bought out by one of the large diagnostic companies. Cologuard will face significant competition in the future but will still play a role. Other companies will have a more diversified portfolio to absorb the slowing or negative growth. The hope was liquid biopsy would be the next growth engine but reading what’s out there we will not be best in class. We should be ok employment wise for a while. Stock price who the heck knows. At some point you have to show a profit unless the growth was off the charts which does not seem to be the case. Fourteen years is a long time and growth is slowing.
Um, this company has issues, but not as many as you think CG is the same as FIT testWhy buy a test that hasn't been improved in 14 years?. The size of sample collected is obscene. Others can do the same test with 1/50th the sample volume. Drop a small sample in mail or at clinic instead of paying ups god knows how much to ship a massive bucket for each patient. Great job Kevin. 100 mil a quarter dropped on R&D and nothing to show since 2012.
I don't think you have any idea the problems ES is facing. Unreliable automation, lack of test growth or adoption, consecutive failed (delayed)launches and studies. Oblivious Exec leadership. The end is nigh.Um, this company has issues, but not as many as you think CG is the same as FIT test
I don't think you have any idea the problems ES is facing. Unreliable automation, lack of test growth or adoption, consecutive failed (delayed)launches and studies. Oblivious Exec leadership. The end is nigh.
Loose money. PG can’t even win their own state from what I hearUnfortunately the problems are costly. PO was supposed to save us and is a disaster. Extra launch failed miserably. MRD launch better knock it out of the ballpark, but it won’t.
What does PG do?
YokelLoose money
so
You have to realize that marketing hires people to judge the effectiveness of all the ads they spend money on.so
We went from music of an old dead guy to trying to play off a show that ended seven years ago and another that’s total brain rot. Well done, marketing. What’s next? Elon Musk sponsorship? JFC